Recent advances in tumor-targeting chemotherapy drugs  

作　　者：Iwao Ojima 

机构地区：[1]Institute of Chemical Biology and Drug Discovery,Stony Brook University,Stony Brook,NY 11794-3400,USA

出　　处：《Cancer Drug Resistance》2021年第3期885-887,共3页癌症耐药（英文）

摘　　要：The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time to review the recent advances in tumor-targeting chemotherapy drugs by collecting articles from leading researchers at the 20th anniversary of the FDA approvals of these two epoch-making anticancer drugs with two different approaches to targeting cancer cells specifically.In this Special Issue,recent advances in these two approaches are presented.

关 键 词：DRUGS CHEMOTHERAPY CANCER 

分 类 号：R73[医药卫生—肿瘤]